16/06/2026
A new diabetes shot may mark the next big leap beyond Ozempic and Mounjaro.
Scientists are now testing retatrutide, an experimental once-weekly injection designed to target three hormone pathways at once: GLP-1, GIP, and glucagon.
That triple action is why some researchers are calling it a “triple-G” metabolic drug.
In a Phase 3 clinical trial involving adults with type 2 diabetes, retatrutide helped patients achieve major improvements in long-term blood sugar control while also producing striking weight loss. At the highest tested dose, participants lost close to 17% of their body weight on average.
Unlike older diabetes medicines that mainly focus on lowering blood sugar, this new class of treatment appears to work more broadly across metabolism. It helps reduce appetite, improve glucose regulation, and may increase energy expenditure.
Researchers are also studying oral options such as orforglipron and elecoglipron, which could one day offer similar benefits without weekly injections.
But experts stress an important point: these drugs are not magic fixes. They can cause side effects such as nausea, vomiting, diarrhea, or constipation, and they work best when combined with proper nutrition, physical activity, and medical supervision.
Still, this is a major sign of where diabetes and obesity treatment may be heading — toward more personalized medicines that target the body’s hormone systems with far greater precision.
Source: Lang, K. (2026). Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports. The BMJ.